文献速递类风湿关节炎

TNFα抑制剂通过减少破骨细胞前体和IL-20独立于临床反应减少RA骨丢失

TNFα inhibitors reduce bone loss in rheumatoid arthritis independent of clinical response by reducing osteoclast precursors and IL-20.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

该研究纳入117例类风湿关节炎(RA)患者,用DEXA测腰椎和股骨颈骨密度、ELISA测骨转换标志物、多因子检测测细胞因子,并体外观察单核细胞向破骨细胞前体(OCP)分化。结果显示TNFα抑制剂改善腰椎骨密度,与DAS28临床反应无关,同时降低血OCP数量和单核细胞体外分化为OCP的能力,并降低RANK表达和IL-20产生;应答者中骨密度改善与IL-20水平降低相关。

要点

  • TNFα抑制剂改善RA患者腰椎骨密度,不依赖DAS28临床应答。
  • 治疗降低血OCP数量及单核细胞体外分化为OCP的能力。
  • 应答者中骨密度改善与IL-20水平降低相关。

核心结论

  • TNFα抑制剂可减少RA患者腰椎骨丢失,且该作用独立于DAS28变化。
  • 骨丢失减少在应答者中与IL-20水平降低相关。

研究设计与样本

  • 研究测量了117例RA患者腰椎和股骨颈骨密度(DEXA扫描)。
  • 用ELISA测骨转换标志物CTX、骨保护素(OPG)、骨钙素和RANKL。
  • 用多因子检测和ELISA测血浆及体外T细胞培养上清中16种细胞因子。
  • 用流式和显微镜测TNFα抑制剂对血单核细胞(MNC)向破骨细胞前体(OCP)分化的影响。

主要发现

  • TNFα抑制剂改善腰椎骨密度,但对血骨转换标志物影响有限,且不依赖患者临床应答。
  • 治疗后血OCP数量和单核细胞体外分化为OCP的能力下降。
  • 治疗还降低RANK表达和IL-20产生。
  • 应答者中骨密度改善与IL-20水平降低相关。

临床怎么用

  • 评估TNFα抑制剂疗效时,除DAS28外应关注骨密度和骨转换指标。
  • 对DAS28应答不佳者,TNFα抑制剂仍可能减少腰椎骨丢失。
  • IL-20水平降低可能提示骨密度改善,尤其见于临床应答者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: About half of RA patients treated with TNFα inhibitors either do not respond or lose their initial therapeutic response over time. The clinical response is measured by reduction in DAS28, which primarily reflects inflammation. However, other effects of TNFα inhibitors, such as impact on bone erosion, are not assessed by DAS28. We aimed to examine the effect of TNFα inhibitors on bone density, bone biomarkers and cytokine production in responder and non-responder patients and assessed mechanisms of action. METHODS: BMD in the lumbar spine and femur neck of 117 RA patients was measured by DEXA scan. Bone turnover biomarkers CTX, osteoprotegerin (OPG), osteocalcin and RANKL were measured by ELISA. Levels of 16 cytokines in plasma and in tissue culture supernatants of ex vivo T cells were measured by multiplex assays and ELISA. The effect of treatment with TNFα inhibitors on blood mononuclear cell (MNC) differentiation to osteoclast precursors (OCP) was measured flow cytometry and microscopy. RESULTS: TNFα inhibitors improved lumbar spine BMD but had modest effects on blood bone biomarkers, irrespective of patients' clinical response. Blood OCP numbers and the ability of monocytes to differentiate to OCP in vitro declined after treatment. Treatment also reduced RANK expression and IL-20 production. BMD improvement correlated with reduced levels of IL-20 in responder patients. CONCLUSION: This study reveals that TNFα inhibitors reduce lumbar spine bone loss in RA patients irrespective of changes in DAS28. The reduction in bone loss is associated with reduction in IL-20 levels in responder patients.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Al-Bogami M, Bystrom J, Clanchy F, et al. TNFα inhibitors reduce bone loss in rheumatoid arthritis independent of clinical response by reducing osteoclast precursors and IL-20. Rheumatology (Oxford). 2021. PMID: 32984900. doi:10.1093/rheumatology/keaa551

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。